• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Ispire Technology Inc. Reports Financial Results for Fiscal Second Quarter 2026

    2/6/26 7:00:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $ISPR alert in real time by email

    Ongoing Focus on Collections Drives 19% Reduction in Net Accounts Receivable since June 30, 2025



    Cash
     of $17.6 Million at December 31, 2025 

    LOS ANGELES, Feb. 6, 2026 /PRNewswire/ -- Ispire Technology Inc. (NASDAQ:ISPR) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today reported financial results for the second quarter of fiscal 2026, for the three months ended December 31, 2025.

    Ispire (PRNewsfoto/Ispire Technology Inc.)

    Fiscal Second Quarter 2026 Financial Results

    • Revenue of $20.3 million versus $41.8 million for the second quarter of fiscal 2025.
    • Gross profit of $3.5 million compared to $7.7 million for the second quarter of fiscal 2025.
    • Gross margin of 17.1% compared to 18.5% for the second quarter of fiscal 2025.
    • Total operating expenses of $10.3 million compared to $15.1 million for the second quarter of fiscal 2025.
    • Net loss of $6.6 million, compared to net loss of $8.0 million in the second quarter of fiscal 2025.

    "This quarter represented an inflection point for Ispire during its yearlong cost cutting and customer quality rationalization efforts and we believe future quarters will see top line growth, consistent cash flows and bottom-line improvement. We are confident we have laid a solid foundation for future success," commented Michael Wang, Co-Chief Executive Officer of Ispire. "During the second quarter of fiscal 2026, we maintained our focus on prioritizing high-quality revenue, and reinforcing our disciplined and intentional approach to sustainable growth. This was particularly evident in our efforts to reduce net accounts receivable, which continues to have strong success. Over the second fiscal quarter we reduced net accounts receivable by 19.5% to $37.9 million, compared to $47.0 million at the end of fiscal year 2025."

    "We continue to lay important groundwork across core areas of the business, including the ramp up of our manufacturing capabilities in Malaysia as we prepare to increase production throughout fiscal 2026. Momentum continues to build for our proprietary G-Mesh technology, with several large and mid-sized nicotine manufacturers engaged in discussions to evaluate its use in next-generation vaping devices, as we work toward potential licensing and partnership opportunities. In addition, our IKE Tech joint venture is making steady global progress, collaborating with regulators across Europe, Southeast Asia, and the Middle East to support the broader adoption of age-gating technology as a safer industry standard.  In the US, although most adult consumers want flavored e-cigarettes, nearly all of the flavored e-cigarettes are both unauthorized by the FDA and sold through illicit channels.  While we welcome the US Federal Government's strengthened enforcement mandate of the illicit trade of vapes, we believe that such enforcement can only be truly effective by pairing it with the creation of a robust, legal market of FDA authorized flavored e-cigarette products. Ispire, with IKE, is a key player in the creation of this market of legal, approved products, using its technologies to both prevent youth-access, ensure product authenticity and provide solutions to secure devices before misuse occurs. This is where we are seeing macro tailwinds in our favor relating to the US FDA's stated position on flavored ENDS products and age-gating. Since October 2025, the FDA's explicit position is that you must have age gating technology if you want flavored products approved. Ispire, through its IKE joint venture, has one of the leading and most low friction technologies in this space, and we look forward to capitalizing on this opportunity in due time", Mr. Wang concluded.

    Jay Yu, Chief Financial Officer of Ispire, said, "The second quarter of fiscal 2026 reflects continued progress as we focused on strengthening the Company's financial foundation. Disciplined cost controls drove a year-over-year decline in operating expenses, which decreased from $15.1 million to $10.3 million over the second fiscal quarter, highlighting the impact of our efficiency initiatives. Our net accounts receivable also declined to $37.9 million as of December 31, 2025, compared with $47.0 million as of June 30, 2025, reflecting our ongoing focus on higher-quality customers. These actions position the Company for enhanced financial flexibility and support sustained value creation over the long term."

    Financial Results for the Fiscal Second Quarter Ended December 31, 2025

    Ispire reported revenue of $20.3 million for the fiscal second quarter ended December 31, 2025, versus $41.8 million for the prior comparable period. The decrease in revenue is due to the strategic shift away from lower quality cannabis customers, resulting in a decrease of overall product sales. 

    For the second quarter of fiscal 2026, gross profit was $3.5 million compared to $7.7 million in the prior comparable quarter. Gross margin was 17.1% compared to 18.5% for the second quarter of fiscal 2025. The decrease in gross margin was primarily due to changes in product mix with less higher margin products being sold during the three months ended December 31, 2025.

    Total operating expenses were $10.3 million for the second fiscal quarter of 2026, compared to $15.1 million for the same period last year.

    Net loss was $6.6 million or $0.12 per share for the fiscal second quarter of 2026, versus a net loss of $8.0 million, or $0.14 per share for the fiscal second quarter of 2025.

    At December 31, 2025, Ispire held cash of $17.6 million and working capital of $3.5 million.

    Conference Call

    The Company will conduct a conference call at 8:00 am ET on Friday, February 6, 2026, to discuss the results, followed by a Q&A session.

    To listen to the conference call, please dial in using the information below. When prompted upon dialing-in, please ask for the "Ispire Technology Call."

    • Date: Friday, February 6, 2026
    • Time: 8:00 am ET
    • Dial-In Numbers: United States 877-451-6152 or International +1 201-389-0879

    This conference call will be webcast live and can be accessed by all interested parties at  https://viavid.webcasts.com/starthere.jsp?ei=1749224&tp_key=1ec45fe266.

    Please access the link at least fifteen minutes prior to the start of the call to register, download, and install any necessary audio software.

    A playback will be available until 11:59 pm ET on Friday, February 20, 2026. To listen, please dial 1-844-512-2921 or 1-412-317-6671. Use the passcode 13758138 to access the replay.

    About Ispire Technology Inc.

    Ispire is engaged in the research and development, design, commercialization, sales, marketing and distribution of branded e-cigarettes and cannabis vaping products. The Company's operating subsidiaries own or license more than 400 patents worldwide. Ispire's branded e-cigarette products are marketed under the Aspire name and are sold worldwide (except in the U.S., People's Republic of China and Russia) primarily through its global distribution network. The Company also engages in original design manufacture (ODM) relationships with e-cigarette brands and retailers worldwide. The Company's cannabis products are marketed under the Ispire brand name primarily on an ODM basis to other cannabis vapor companies. Ispire sells its cannabis vaping hardware in the US, Europe and South Africa and it recently commenced marketing activities and customer engagement in Canada and Latin America. For more information, visit www.ispiretechnology.com or follow Ispire on Instagram, LinkedIn, Twitter and YouTube.

    Forward Looking Statements

    This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended ("Securities Act") as well as Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended, that are intended to be covered by the safe harbor created by those sections. Forward-looking statements, which are based on certain assumptions and describe the Company's future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "would," "could," "seek," "intend," "plan," "goal," "project," "estimate," "anticipate," "strategy," "future," "likely" or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the Company's strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Important factors that could cause the Company's actual results and financial condition to differ materially from those indicated in the forward-looking statements. Such forward-looking statements include, but are not limited to, risks and uncertainties including those regarding: whether the Company may be successful in re-entering the U.S. ENDS market; the approval or rejection of any PMTA submitted by the Company; whether the Company will be successful in its plans to further expand into the African market; whether the Company's joint venture with Touch Point Worldwide Inc. d/b/a/ Berify and Chemular Inc. (the "Joint Venture") may be successful in achieving its goals as currently contemplated, with different terms, or at all; the Joint Venture's ability to innovate in the e-cigarette technology space or develop age gating or age verification technologies for nicotine vaping devices; the Company's ability to collect its accounts receivable in a timely manner; the Company's business strategies; the ability of the Company to market to the Ispire ONE™; Ispire ONE™'s success in meeting its goals; the ability of its customers to derive the anticipated benefits of the Ispire ONE™ and the success of its products on the markets; the Ispire ONE™ proving to be safe; and the risk and uncertainties described in "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations," "Cautionary Note on Forward-Looking Statements" and the additional risk described in Ispire's Annual Report on Form 10-K for the year ended June 30, 2025 and any subsequent filings which Ispire makes with the SEC. You should not rely upon forward-looking statements as predictions of future events. The forward-looking statements made in this press release relate only to events or information as of the date on which the statements are made in this press release. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events except as required by applicable law. You should read this press release with the understanding that our actual future results may be materially different from what we expect.

     

    ISPIRE TECHNOLOGY INC.

    UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

    (In $USD, except share and per share data) 

     







    December 31,

    2025





    June 30,

    2025



    Assets













    Current assets:













    Cash



    $

    17,565,334





    $

    24,351,765



    Restricted cash





    50,000







    -



    Accounts receivable, net





    37,878,353







    39,664,145



    Inventories





    5,037,414







    6,647,970



    Prepaid expenses and other current assets





    3,120,978







    2,244,505



    Total current assets





    63,652,079







    72,908,385



    Non-current assets:

















    Accounts receivable, net of current portion





    -







    7,367,158



    Property, plant and equipment, net





    2,599,861







    2,952,800



    Intangible assets, net





    2,474,037







    2,232,620



    Right-of-use assets – operating leases





    4,335,355







    5,030,005



    Other investment





    2,000,000







    2,000,000



    Equity method investment





    9,129,213







    9,515,546



    Other non-current assets





    210,617







    210,617



    Total non-current assets





    20,749,083







    29,308,746



    Total assets



    $

    84,401,162





    $

    102,217,131



    Liabilities and stockholders' equity

















    Current liabilities

















    Accounts payable



    $

    3,137,235





    $

    4,172,476



    Accounts payable – related party





    42,444,624







    52,420,256



    Contract liabilities





    4,971,135







    4,861,250



    Accrued liabilities and other payables





    6,818,397







    8,099,991



    Income tax payable





    12,590







    -



    Borrowing – current portion





    1,146,766







    1,146,766



    Operating lease liabilities – current portion





    1,659,698







    1,838,815



    Total current liabilities





    60,190,445







    72,539,554





















    Non-current liabilities:

















    Amount due to a related party





    29,000,000







    25,000,000



    Borrowing – net of current portion





    231,978







    805,361



    Operating lease liabilities – net of current portion





    2,642,156







    3,267,522



    Total non-current liabilities





    31,874,134







    29,072,883



    Total liabilities





    92,064,579







    101,612,437





















    Commitments and contingencies



































    Stockholders' (deficit)/equity:

















    Common stock, par value $0.0001 per share; 140,000,000 shares authorized;

         57,289,864 and 57,193,734 shares issued and outstanding as of December 31,

         2025 and June 30, 2025





    5,729







    5,719



    Treasury stock, at cost





    (105,489)







    (60,488)



    Additional paid-in capital





    50,593,580







    48,833,601



    Accumulated deficit





    (57,927,041)







    (48,065,267)



    Accumulated other comprehensive loss





    (230,196)







    (108,871)



    Total stockholders' (deficit)/equity





    (7,663,417)







    604,694



    Total liabilities and stockholders' (deficit)/equity



    $

    84,401,162





    $

    102,217,131



     

    ISPIRE TECHNOLOGY INC.

    UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND

    COMPREHENSIVE LOSS

    (In $USD, except share and per share data)

     







    Three Months Ended

    December 31,





    Six Months Ended

    December 31,







    2025





    2024





    2025





    2024





























    Revenue



    $

    20,286,556





    $

    41,827,860





    $

    50,637,440





    $

    81,166,173





































    Cost of revenue





    16,811,955







    34,105,289







    42,016,067







    65,769,224





































    Gross profit





    3,474,601







    7,722,571







    8,621,373







    15,396,949





































    Operating expenses:

































    Sales and marketing expenses





    1,476,328







    2,061,664







    3,041,172







    5,053,911



    Credit loss expenses





    4,209,201







    4,183,998







    5,973,453







    7,286,079



    General and administrative expenses





    4,663,939







    8,836,964







    9,176,924







    15,679,883





































    Total Operating expenses





    10,349,468







    15,082,626







    18,191,549







    28,019,873





































    Loss from operations





    (6,874,867)







    (7,360,055)







    (9,570,176)







    (12,622,924)





































    Other income (expense):

































    Interest income





    104,922







    59,755







    200,394







    59,841



    Interest expense





    (100,191)







    (13,073)







    (212,367)







    (24,537)



    Exchange gain (loss), net





    290,237







    (245,173)







    300,039







    (127,588)



    Other income, net





    83,574







    19,934







    12,991







    38,333





































    Total Other income (expense), net





    378,542







    (178,557)







    301,057







    (53,951)





































    Loss before income taxes





    (6,496,325)







    (7,538,612)







    (9,269,119)







    (12,676,875)





































    Income taxes





    (106,586)







    (460,031)







    (592,655)







    (916,784)





































    Net loss



    $

    (6,602,911)





    $

    (7,998,643)





    $

    (9,861,774)





    $

    (13,593,659)





































    Other comprehensive income (loss)

































    Foreign currency translation adjustments





    (113,433)







    73,470







    (121,325)







    (81,467)



    Comprehensive loss



    $

    (6,716,344)





    $

    (7,925,173)





    $

    (9,983,099)





    $

    (13,675,126)





































    Net loss per share

































    Basic and diluted



    $

    (0.12)





    $

    (0.14)





    $

    (0.17)





    $

    (0.24)





































    Weighted average shares outstanding:

































    Basic and diluted





    57,258,218







    56,658,012







    57,257,938







    56,629,666



     

    For more information, kindly contact:

    IR Contacts:

    KCSA Strategic Communications

    Phil Carlson

    212-896-1233

    ispire@kcsa.com



    PR Contact:

    Ellen Mellody

    570-209-2947

    EMellody@kcsa.com

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/ispire-technology-inc-reports-financial-results-for-fiscal-second-quarter-2026-302680862.html

    SOURCE Ispire Technology Inc.

    Get the next $ISPR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ISPR

    DatePrice TargetRatingAnalyst
    5/20/2024$11.00Buy
    ROTH MKM
    More analyst ratings

    $ISPR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ROTH MKM initiated coverage on Ispire Technology with a new price target

    ROTH MKM initiated coverage of Ispire Technology with a rating of Buy and set a new price target of $11.00

    5/20/24 7:18:59 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    $ISPR
    SEC Filings

    View All

    SEC Form 10-Q filed by Ispire Technology Inc.

    10-Q - Ispire Technology Inc. (0001948455) (Filer)

    2/6/26 4:30:49 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 10-Q filed by Ispire Technology Inc.

    10-Q - Ispire Technology Inc. (0001948455) (Filer)

    11/6/25 4:31:10 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 10-K filed by Ispire Technology Inc.

    10-K - Ispire Technology Inc. (0001948455) (Filer)

    9/15/25 4:06:16 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    $ISPR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Fargis John sold $14,625 worth of shares (7,500 units at $1.95), decreasing direct ownership by 16% to 39,099 units (SEC Form 4)

    4 - Ispire Technology Inc. (0001948455) (Issuer)

    11/24/25 4:30:02 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    CLO and Secretary Pryzbyla Steven P. sold $45,001 worth of shares (17,046 units at $2.64), decreasing direct ownership by 4% to 399,664 units (SEC Form 4)

    4 - Ispire Technology Inc. (0001948455) (Issuer)

    10/2/25 4:30:03 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Cox Brent was granted 29,784 shares, increasing direct ownership by 142% to 50,782 units (SEC Form 4)

    4 - Ispire Technology Inc. (0001948455) (Issuer)

    7/11/25 4:31:16 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    $ISPR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Ispire Technology Inc. Reports Financial Results for Fiscal Second Quarter 2026

    Ongoing Focus on Collections Drives 19% Reduction in Net Accounts Receivable since June 30, 2025Cash of $17.6 Million at December 31, 2025  LOS ANGELES, Feb. 6, 2026 /PRNewswire/ -- Ispire Technology Inc. (NASDAQ:ISPR) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today reported financial results for the second quarter of fiscal 2026, for the three months ended December 31, 2025. Fiscal Second Quarter 2026 Financial Results Revenue of $20.3 million versus $41.8 million for the second quarter of fiscal 2025.Gross profit

    2/6/26 7:00:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Ispire-Backed IKE Tech Invited to Participate in FDA Roundtable on PMTA Submissions

    Invitation-Only Forum Underscores FDA Recognition of IKE Tech as a Key Stakeholder and Highlights the Strategic Role of Age-Gating Technology in the Future of ENDS Regulation and Compliance LOS ANGELES, Feb. 4, 2026 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or the "Company") (NASDAQ:ISPR), a trailblazer in vaping technology and precision dosing, announced that IKE Tech LLC ("IKE Tech" or "IKE"), a joint venture that includes Ispire as a founding partner, has been invited by the U.S. Food and Drug Administration (FDA) to participate in its Roundtable Discussion with Small ENDS Manufacturers on Premarket Tobacco Product Application (PMTA) Submissions.

    2/4/26 8:30:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    WM Technology, Inc. Appoints Harry DeMott and Brent Cox to Board of Directors and Announces Executive Employment Arrangement with CFO Susan Echard

    WM Technology, Inc. ("WM Technology" or the "Company") (NASDAQ:MAPS), a leading marketplace and technology solutions provider to the cannabis industry, today announced the appointment of Harry DeMott and Brent Cox to the Company's Board of Directors, effective February 1, 2026. The Company also announced that Susan Echard will continue to serve as Chief Financial Officer, transitioning from a contracted arrangement to employment with the Company, effective January 30, 2026. "We are pleased to welcome Harry and Brent to WM Technology's Board of Directors. They each bring a combination of cannabis industry perspective, technology fluency, and disciplined capital markets experience," said Do

    2/3/26 5:45:00 PM ET
    $ISPR
    $MAPS
    Medicinal Chemicals and Botanical Products
    Health Care
    Computer Software: Prepackaged Software
    Technology

    $ISPR
    Financials

    Live finance-specific insights

    View All

    Ispire Technology Inc. Reports Financial Results for Fiscal Second Quarter 2026

    Ongoing Focus on Collections Drives 19% Reduction in Net Accounts Receivable since June 30, 2025Cash of $17.6 Million at December 31, 2025  LOS ANGELES, Feb. 6, 2026 /PRNewswire/ -- Ispire Technology Inc. (NASDAQ:ISPR) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today reported financial results for the second quarter of fiscal 2026, for the three months ended December 31, 2025. Fiscal Second Quarter 2026 Financial Results Revenue of $20.3 million versus $41.8 million for the second quarter of fiscal 2025.Gross profit

    2/6/26 7:00:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Ispire Technology Inc. Schedules Fiscal Second Quarter 2026 Earnings Conference Call

    LOS ANGELES, Feb. 3, 2026 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or the "Company") (NASDAQ:ISPR), a trailblazer in vaping technology and precision dosing, announced today that it will host its earnings conference call at 8:00 am ET on Friday, February 6, 2026, to discuss the Company's financial results for its fiscal second quarter ended December 31, 2025. To listen to the conference call, please dial in using the information below. When prompted upon dialing-in, please ask for the "Ispire Technology Call." Date: Friday, February 6, 2026Time: 8:00 am ETDial-In Number

    2/3/26 7:00:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Ispire Technology Inc. Schedules Fiscal First Quarter 2026 Earnings Conference Call

    LOS ANGELES, Nov. 4, 2025 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or the "Company") (NASDAQ:ISPR), a trailblazer in vaping technology and precision dosing, announced today that it will host its earnings conference call at 8:00 am ET on Thursday, November 6, 2025, to discuss the Company's financial results for its fiscal first quarter ended September 30, 2025. To listen to the conference call, please dial in using the information below. When prompted upon dialing-in, please ask for the "Ispire Technology Call." Date: Thursday, November 6, 2025Time: 8:00 am ETDial-In Nu

    11/4/25 4:05:00 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    $ISPR
    Leadership Updates

    Live Leadership Updates

    View All

    WM Technology, Inc. Appoints Harry DeMott and Brent Cox to Board of Directors and Announces Executive Employment Arrangement with CFO Susan Echard

    WM Technology, Inc. ("WM Technology" or the "Company") (NASDAQ:MAPS), a leading marketplace and technology solutions provider to the cannabis industry, today announced the appointment of Harry DeMott and Brent Cox to the Company's Board of Directors, effective February 1, 2026. The Company also announced that Susan Echard will continue to serve as Chief Financial Officer, transitioning from a contracted arrangement to employment with the Company, effective January 30, 2026. "We are pleased to welcome Harry and Brent to WM Technology's Board of Directors. They each bring a combination of cannabis industry perspective, technology fluency, and disciplined capital markets experience," said Do

    2/3/26 5:45:00 PM ET
    $ISPR
    $MAPS
    Medicinal Chemicals and Botanical Products
    Health Care
    Computer Software: Prepackaged Software
    Technology

    Ispire-Backed IKE Tech to Spotlight Breakthroughs in Vape Safety and Harm Reduction at World Vape Show Dubai

    President of Ike Tech and SVP of International Nicotine at Ispire, John Patterson, to Join Global Leaders on Industry Innovation Panel LOS ANGELES, June 16, 2025 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or the "Company") (NASDAQ:ISPR), a global leader in vaporization technology and precision dosing, announced its joint venture IKE Tech LLC ("IKE Tech") will spotlight Ike Tech's blockchain based point of use age-gating and Smart-Tag authentication technologies at the World Vape Show Dubai, June 18–20, 2025. John Patterson, president of Ike Tech and senior vice president of International Nicotine at Ispire, will be featured on a high-level panel titled "Innovations in Consumer Safety

    6/16/25 8:30:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Ispire Technology Inc. Announces Appointment of Jay Yu as Chief Financial Officer

    Jie "Jay" Yu has a strong track record of excellence in public company accounting, and has served in the role of Vice President of Finance for Ispire since June 2023 Ispire also further streamlines operations by cutting an estimated $3.6 million in annual payroll in May 2025 Ispire expects to also cut up to an additional $6.6 million in annual operating expenses over the next three months, for a total estimated annualized expense reduction of $10.2 million LOS ANGELES, May 15, 2025 /PRNewswire/ -- Ispire Technology Inc. (NASDAQ:ISPR) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today announced the appointment of Jie "Jay" Yu as the

    5/15/25 4:30:00 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    $ISPR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Ispire Technology Inc.

    SC 13G - Ispire Technology Inc. (0001948455) (Subject)

    7/12/24 5:00:02 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care